methyl N-butyl-N-methylcarbamate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl N-butyl-N-methylcarbamate
• 英文别名: Methyl butylmethylcarbamate
• 化学式: C₇H₁₅NO₂
• 分子量: 145.202
• InChiKey: NAYDYXLJOVNQPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  甲醇 、 methyl N-butyl-N-methylcarbamate 生成 methyl N-butyl-N-(methoxymethyl)carbamate
  参考文献：
  名称：

  Electroorganic chemistry. XX. Anodic oxidation of carbamates

  摘要：

  DOI：

  10.1021/ja00848a020
• 作为产物：
  描述：

  在 三氟甲磺酸 、 tetrabutylammonium tetrafluoroborate 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 以40%的产率得到N,N'-dibutyl-N,N'-bis(methoxycarbonyl)-1,2-ethanediamine
  参考文献：
  名称：

  通过减少阳离子池产生碳自由基

  摘要：

  通过“阳离子池”法产生的 N-酰基铵离子的电化学还原导致碳自由基的形成。由此产生的碳自由基经历了均聚...

  DOI：

  10.1246/bcsj.77.1545

文献信息

• METHODS FOR INHIBITING DRUG DEGRADATION
  申请人：SEQUOIA PHARMACEUTICALS, INC.

  公开号：US20150284352A1

  公开（公告）日：2015-10-08

  Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.

  提供了一种抑制细胞色素P450酶的方法，可用于改善疾病治疗，防止药物或其他分子被细胞色素P450降解。提供了可以充当增强剂的药物组合物，以改善药物的药代动力学，增加生物利用度，并增强那些在体内被细胞色素P450酶降解的药物的治疗效果。
• [EN] CARM1 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE CARM1 ET LEURS UTILISATIONS
  申请人：EPIZYME INC

  公开号：WO2014144169A1

  公开（公告）日：2014-09-18

  Provided herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R1, R1a, R2a, R2b, R2c, R2d, are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula (II) wherein L2, R13, G8, G10, G11, and G12 are as defined herein. Compounds of the present invention are useful for inhibiting CARMl activity. Methods of using the compounds for treating CARM1 -mediated disorders are also described.

  本文提供了式（I）的化合物及其药用盐，以及药物组合物；其中X、R1、R1a、R2a、R2b、R2c、R2d如本文所定义，环HET是式（II）的6-成员单环杂环芳基环系统，其中L2、R13、G8、G10、G11和G12如本文所定义。本发明的化合物可用于抑制CARM1活性。还描述了使用这些化合物治疗CARM1介导的疾病的方法。
• [EN] COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER<br/>[FR] COMPOSÉS, COMPOSITIONS ET MÉTHODES DE TRAITEMENT DU CANCER
  申请人：HOTSPOT THERAPEUTICS INC

  公开号：WO2022221704A1

  公开（公告）日：2022-10-20

  The present disclose includes, among other things, compounds that treat or lessen the severity of cancer, pharmaceutical compositions and methods of making and using the same.

  本公开涉及的内容包括用于治疗或减轻癌症严重程度的化合物、制药组合物以及制备和使用这些化合物的方法。
• Process for preparing N,O-dialkylhydroxycarbamic acid esters
  申请人：MITSUI PETROCHEMICAL INDUSTRIES, LTD.

  公开号：EP0581613A1

  公开（公告）日：1994-02-02

  A process for preparing an N,O-dialkylhydroxycarbamic acid ester, which comprises reacting hydroxylamine or a salt thereof with a dihydrocarbyl carbonate in the presence of a base to prepare hydroxycarbamic acid ester, and subsequently alkylating this compound with an alkylating agent; a process for recovering an N,O-dialkylhydroxycarbamic acid ester, which comprises azeotropically distilling the ester with water from a solution containing the ester; a process for preparing an N,O-dialkylhydroxylamine, which comprises hydrolyzing an N,O-dialkylhydroxycarbamic acid ester in an aqueous solvent in the presence of an alkali ; a process for purifying an N,O-dialkylhydroxylamine hydrochloride, which comprises adding an aldehyde or a ketone to a solution of an N,O-dialkylhydroxylamine hydrochloride containing an O-alkylhydroxylamine hydrochloride as an impurity to convert the O-alkylhydroxylamine hydrochloride into O-alkyl aldoxime or O-alkyl ketoxime, and subsequently separating the N,O-dialkylhydroxylamine hydroxhloride from the reaction system ; and a process for separating a N,O-dialkylhydroxylamine hydrochloride, which comprises (i) adding benzene or alkylated benzene to an aqueous solution containing the N,O-dialkylhydroxylamine hydrochloride, azeotropically removing water or a hydrochloride solution, and subsequently (ii) adding an alcohol to obtain the N,O-dialkylhydroxylamine hydrochloride in crystal form.

  一种制备 N,O-二烷基羟基氨基甲酸酯的工艺，包括在碱存在下使羟胺或其盐与二氢羰基碳酸酯反应制备羟基氨基甲酸酯，然后用烷基化剂使该化合物烷基化；一种回收 N,O-二烷基羟基氨基甲酸酯的工艺，包括从含有该酯的溶液中用水共沸蒸馏该酯； 一种制备 N,O-二烷基羟基胺的工艺，包括在碱存在下在水性溶剂中水解 N,O-二烷基羟基氨基甲酸酯；一种提纯 N,O-二烷基羟胺盐酸盐的工艺，包括向含有 O-烷基羟胺盐酸盐作为杂质的 N,O-二烷基羟胺盐酸盐溶液中加入醛或酮，将 O-烷基羟胺盐酸盐转化为 O-烷基醛肟或 O-烷基酮肟，然后将 N,O-二烷基羟胺盐酸盐从反应体系中分离出来；以及一种分离 N,O-二烷基羟胺盐酸盐的工艺，包括(i)向含有 N,O-二烷基羟胺盐酸盐的水溶液中加入苯或烷基化苯，共沸除去水或盐酸盐溶液，然后(ii)加入醇，以获得晶体状的 N,O-二烷基羟胺盐酸盐。
• A process for producing substituted amines and a method for purifying synthetic intermediates therefor
  申请人：MITSUI PETROCHEMICAL INDUSTRIES, LTD.

  公开号：EP0678504A2

  公开（公告）日：1995-10-25

  A process for producina a substituted amine of formula (IV) : wherein R2 is hydrogen, a hydrocarbon group or a heteroatom-containing hydrocarbon group, and R3 is a hydrocarbon group or a heteroatom-containing hydrocarbon group, which process comprises : (a) reacting a hydroxamic acid of formula (II) : wherein R1 is hydrogen or a hydrocarbon group, in the presence of a base with a reagent capable of introducing a hydrocarbon group or a heteroatom-containing hydrocarbon group onto an oxygen atom and/or a nitrogen atom to form a substituted hydroxamic acid of formula (III) : wherein R1, R2 and R3 are as defined above, and (b) hydrolyzing the substituted hydroxamic acid of formula (III) in the presence of a base or an acid to produce a substituted amine of formula (IV) : wherein R2 and R3 are as defined above.

  一种生产式(IV)取代胺的工艺： 其中 R2 是氢、烃基或含杂原子的烃基，R3 是烃基或含杂原子的烃基，该工艺包括： (a) 使式(II)的羟肟酸反应： 其中 R1 为氢或烃基，在碱存在下，与能将烃基或含杂原子的烃基引入氧原子和/或氮原子的试剂反应，生成式 (III) 的取代羟肟酸： 其中 R1、R2 和 R3 如上定义，以及 (b) 在碱或酸存在下水解式(III)的取代羟肟酸，生成式(IV)的取代胺： 其中 R2 和 R3 如上文所定义。